Search Results 1781-1790 of 17348 for magnesiummagnesium

1. A Study to Evaluate the Safety and Effectiveness of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease - Mayo Clinic

   Subject may be receiving corticosteroid therapy provided that the dose is ≤ 1 mg/kg/day of systemic prednisone or equivalent and has been stable for at least 2 ...

2. A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer) - Mayo Clinic

   Urinary protein is > 1 + on dipstick and the required following 24-hour urine collection shows urinary protein > 2000 mg;; Serious or non-healing wound ...

3. A Study of Atezolizumab Alone or Combined with Immunomodulatory Drug and/or Daratumumab in Multiple Myeloma Patients - Mayo Clinic

   Creatinine ≤ 2.0 milligrams per deciliter (mg/dL), with creatinine clearance (CrCl) using the Cockcroft-Gault formula ≥ 40 milliliters per minute (mL/min) ...

4. A Study to Evaluate the Accuracy of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

   oral corticosteroids at a dose of greater than 40 mg of prednisone or its equivalent per day. Have received, or are expected to receive, any live viral or ...

5. Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer - Mayo Clinic

   Creatinine less than 1.4 mg/dl; Bilirubin less than or equal to 1.5 x institutional/laboratory upper limit of normal (ULN); Aspartate aminotransferase (AST) ...

6. Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer - Mayo Clinic

   ... mg/dL OR calculated (calc.) creatinine clearance >= 60 mL/min; Bilirubin =< 1.5 x ULN; Aspartate aminotransferase (AST) =< 2.5 x ULN; Although they will not be ...

7. A Study to Evaluate the Effectiveness and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

   ... mg/dL * Planned first-line chemotherapy contains bortezomib administered subcutaneously weekly. Inclusion Criteria for Open-label (OLE) Phase: * Must not ...

8. A Study To Evaluate The Efficacy And Safety Of GDC-8264 In Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) And Major Adverse Kidney Events (MAKE) - Mayo Clinic

   ... (mg/dL)} 3. Stable kidney function with no known episodes of AKI within 2 weeks of screening. Exclusion Criteria: 1. Need for renal replacement therapy ...

9. A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

   Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) and NSAIDs are permitted if the patient is on a stable dose regimen for. 2 weeks prior to and ...

10. A Study of X4P-001 in Patients with Advanced Renal Cell Carcinoma - Mayo Clinic

    Has, within 2 weeks prior to day 1, received systemic corticosteroids exceeding prednisone 10 mg per day or equivalent: For other immunosuppressive agents ...